ACCESS-AD: a new European initiative to accelerate timely and equitable AD diagnosis, treatment and care
Grant and Award Announcement
Updates every hour. Last Updated: 20-Jun-2026 12:15 ET (20-Jun-2026 16:15 GMT/UTC)
Developed by a consortium of 30 public and private partners, ACCESS-AD (“Advancing Clinical Care and Equity through Scalable Solutions in Alzheimer’s Disease diagnosis and treatment”) is focused on bringing innovations to routine clinical practice for Alzheimer’s disease, supporting timely diagnosis, treatment and monitoring across diverse healthcare settings. Launching on 13 January 2026, ACCESS-AD is funded for a period of 5 years by the Innovative Health Initiative (IHI), an EU Public-Private Partnership supporting health research and innovation.
As Australians return to work after the holidays, many will be reflecting on their health and wellbeing goals for the year ahead. New research reveals that while workplace factors like long hours, work-related stress and shift work do influence high-risk drinking, personal and social factors play an even bigger role.
Findings reveal a general decline in vaccine hesitancy during the 15 months following the COVID-19 vaccine roll-out in 2021-2022, with almost two-thirds of those initially hesitant going on to receive one or more COVID-19 vaccinations.
The most common reasons for original COVID-19 vaccine hesitancy were concerns around vaccine effectiveness and side effects. But people who cited these reasons for hesitancy were more likely to change their minds and subsequently get vaccinated.
In contrast, participants who reported being hesitant because of a generalised anti-vaccine sentiment, a mistrust of vaccine developers, or having a low perceived risk from COVID-19 remained more reluctant to receive a COVID-19 vaccine.
The authors say that public health officials and policymakers need to recognise that certain types of vaccine hesitancy are highly context-specific and may be more readily addressed, while others are more resistant to change.